The heart, kidney, and brain as target organs in hypertension

Cardiology Clinics

Volumn 20, Issue 2, 2002, Pages 225-247

  Mensah, George A ^a   Croft, Janet B ^a   Giles, Wayne H ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDRALAZINE; ISOSORBIDE DINITRATE; MINOXIDIL; NIFEDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN INJURY; DISABILITY; HEART DEATH; HEART INJURY; HUMAN; HYPERTENSION; KIDNEY INJURY; LIFESTYLE; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TARGET ORGAN; BRAIN DISEASE; FEMALE; HEART DISEASE; KIDNEY DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BRAIN DISEASES; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 0035987975     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(02)00004-8     Document Type: Article

References (159)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
2. Minimal change hypertensive retinopathy and arterial pre-hypertension, illustrated via ambulatory blood pressure monitoring in putatively normotensive subjects
3. Does increased blood pressure cause left ventricular hypertrophy or vice versa?
4. Prediction of left ventricular mass in youth with family histories of essential hypertension
5. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview
6. Role of the cardiac renin-angiotensin system in hypertensive cardiac hypertrophy
7. The renin-angiotensin system and vascular hypertrophy
8. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy
9. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy
10. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography
11. The role of intraglomerular pressure in the initiation and progression of renal disease
12. Nephron mass as a risk factor for progression of renal disease
13. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
14. Hemodynamic theory of progressive renal disease: A 10-year update in brief review
15. Renal parenchymal involvement in essential hypertension
16. Hypertension mechanisms causing stroke
17. The eye in hypertension
18. Are retinal arteriolar abnormalities related to atherosclerosis? The Atherosclerosis Risk in Communities Study
19. The eye as a target organ: An updated classification of hypertensive retinopathy
20. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS)
21. Determinants of left ventricular hypertrophy and function in hypertensive patients
22. Echocardiographic features of malignant hypertension
23. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension
24. Salt intake: Potential deleterious effects excluding blood pressure
25. Salt intake as a determinant of cardiac hypertrophy
26. Salt sensitivity and left ventricular hypertrophy
27. Obesity increases the prevalence of left ventricular hypertrophy in arterial hypertension
28. Left ventricular hypertrophy. Its relationship to obesity and hypertension
29. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
30. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
31. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults
32. Left ventricular hypertrophy and geometry in a population sample of elderly males
33. Relations of left ventricular geometry and function to body composition in children with high casual blood pressure
34. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension
35. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads
36. Cost-effectiveness of echocardiography and electrocardiography for detection of left ventricular hypertrophy in patients with systemic hypertension
37. Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence
38. Cardioprotection and antihypertensive therapy: The key importance of addressing the associated coronary risk factors (the Framingham experience)
39. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension
40. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The prospective randomized enalapril study evaluating regression of ventricular enlargement (PRE-SERVE) trial
41. Regression of left ventricular hypertrophy and improved prognosis: Some hope now or hype?
42. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy
43. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry
44. Left ventricular hypertrophy at the limits
45. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension
46. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials
47. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: The LIFE Study
48. Relation of obesity, high sodium intake, and eccentric left ventricular hypertrophy to left ventricular exercise dysfunction in essential hypertension
49. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults
50. Dietary calcium induces regression of left ventricular hypertrophy in hypertensive non-insulin-dependent diabetic blacks
51. Congestive heart failure from left ventricular diastolic dysfunction in systemic hypertension
52. Prevalence of isolated left ventricular diastolic dysfunction in hypertension as assessed by combined transmitral and pulmonary vein flow Doppler study
53. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective
54. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort
55. Myocardial collagen matrix remodelling in arterial hypertension
56. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management
57. Left ventricular diastolic dysfunction in patients with congestive heart failure
58. Congestive heart failure with normal systolic function
59. Diastolic dysfunction in congestive heart failure
60. Intact systolic left ventricular function in clinical congestive heart failure
61. Hypertensive hypertrophic cardiomyopathy of the elderly
62. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: From the Investigators of Consensus on Diastolic Dysfunction by Echocardiography
63. Radionuclide angiographic evaluation of left ventricular diastolic function
64. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
65. Cardioreparation with lisinopril in the management of hypertension and heart failure
66. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction
67. Effects of antihypertensive therapy on diastolic dysfunction in left ventricular hypertrophy
68. Left ventricular diastolic dysfunction in hypertension
69. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
70. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
71. Asymptomatic left ventricular dysfunction in the community
72. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
73. The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure
74. The progression from hypertension to congestive heart failure
75. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
76. Tissue renin-angiotensin system in myocardial hypertrophy and failure
77. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III
78. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
79. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
80. An overview of contemporary etiologies of congestive heart failure
81. The epidemiology of heart failure: The Framingham Study
82. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus
83. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites
84. Increased pulse pressure and risk of heart failure in the elderly
85. Risk factors for heart failure in the elderly: A prospective community-based study
86. Guidelines for the diagnosis of heart failure
87. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)
88. Diagnosis and management of heart failure
89. Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction
90. New Zealand guidelines for the management of chronic heart failure
91. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
92. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
93. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial. The Losartan Heart Failure Survival Study ELITE II
94. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
95. Race and responsiveness to drugs for heart failure
96. Race and responsiveness to drugs for heart failure
97. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure
98. Blood pressure as a cardiovascular risk factor: Prevention and treatment
99. Cardiovascular risk assessment in hypertension
100. Prediction of coronary heart disease using risk factor categories
101. Coronary heart disease risk factors and attributable risks in African-American women and men: NHANES I epidemiologic follow-up study
102. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth
103. Pathobiological determinants of atherosclerosis in youth (PBDAY Study), 1986-96
104. Atherosclerosis in the pediatric age with special reference to initiation, progression and regression of atherosclerotic lesions
105. Pathology of atherosclerosis in youth
106. Origin of atherosclerosis in childhood and adolescence
107. Natural history of aortic and coronary atherosclerotic lesions in youth: Findings from the PDAY Study
108. Histologic features of atherosclerosis and hypertension from autopsies of young individuals in a defined geographic population: The Bogalusa Heart Study
109. Endothelial dysfunction in atherosclerosis
110. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels
111. Atherosclerotic plaque rupture: A fatigue process?
112. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
113. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment
114. Precursors of sudden coronary death. Factors related to the incidence of sudden death
115. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates
116. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study
117. Prevalence of late ventricular potentials in hypertensive patients
118. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
119. Impact of atrial fibrillation on mortality, stroke, and medical costs
120. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy
121. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
122. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease
123. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis
124. Aortic dissection
125. Epidemiology and clinicopathology of aortic dissection
126. Prevalence of abdominal aortic aneurysm associated with hypertension in an urban population
127. Peripheral arterial disease epidemiological aspects
128. Update on some epidemiologic features of intermittent claudication: The Framingham Study
129. Vascular effects of systemic hypertension
130. Aortic and large artery stiffness: Current methodology and clinical correlations
131. Peripheral arterial disease detection, awareness, and treatment in primary care
132. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index
133. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg
134. Predictors of death from aortic aneurysm among middle-aged men: The Whitehall study
135. Prevalence of abdominal aortic aneurysm in a hypertensive population
136. Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication
137. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication
138. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials
139. Some characteristics related to the incidence of cardiovascular disease and death: The Framingham Heart Study. 18 Year follow-up
140. Blood pressure, stroke, and coronary heart disease: Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
141. Risk management in stroke prevention: Major clinical trials in hypertension
142. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
143. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
144. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?
145. Stroke prevention: Hypertension, diabetes, tobacco, and lipids
146. Ischemic renal diseases: New insights into old entities
147. Hypertension and ischemic nephropathy
148. Nephron heterogeneity: Clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment
149. Renoprotection: One or many therapies?
150. Renal protective potential of antihypertensive drugs
151. Preserving renal function in adults with hypertension and diabetes: A consensus approach
152. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
153. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
154. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
155. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
156. The ravages of hypertension: A full color demonstration of the spectrum of target organ damage for use in hypertension education